Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non-valvular atrial fibrillation.

Date publication

novembre 2018

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COTTIN Yves

Tous les auteurs :
Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30423205

Résumé

We compared the 1-year safety and effectiveness of dabigatran 110 mg (D110) or 150 mg (D150) to vitamin K antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF), METHODS: New user cohort study of patients dispensed D110 or D150 vs. VKA in 2013 for NVAF, followed 1 year in the French Système National des Données de Santé (SNDS, 66 million persons). D110 and D150 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score (hdPS). Hazard ratios (HR [95% confidence intervals]) for stroke and systemic embolism (SSE), major bleeding (MB), and death were computed using Cox proportional hazards or Fine and Gray models during exposure.

Mots clés

comparative effectiveness, dabigatran, dose-effect, pharmacoepidemiology, vitamin K antagonists

Référence

Br J Clin Pharmacol. 2018 Nov 13;: